New preclinical evidence suggests a circulating bacterial metabolite can weaken CD19 CAR-T cells in vitro. Researchers report that 1,5-pentanediamine—detected in patients colonized with carbapenem-resistant Klebsiella pneumoniae—impaired CAR-T function under laboratory conditions. The findings, published in Cancer Immunology, Immunotherapy, point to a possible mechanism by which microbiome-derived small molecules may create an immunotherapy-tolerant environment. A metabolite-centric mechanism could influence patient selection, antimicrobial stewardship, or combination strategies around CAR-T. For cell-therapy teams, the study adds another variable to the expanding framework of host factors and microbe–immune interactions that affect persistence and efficacy.